A Retrospective evaluation of completion rates, total cost, and adverse effects for treatment of latent tuberculosis infection in a public health clinic in central massachusetts

Clinical Infectious Diseases

Volumn 49, Issue 3, 2009, Pages 424-427

  Young, Heather ^a   Wessolossky, Mireya ^a,b   Ellis, Jeanne ^b   Kaminski, Martin ^a   Daly, Jennifer S ^a,b  

^a UNIVERSITY OF MASSACHUSETTS   (United States)

^b Family Health Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; RIFAMPICIN;

ADULT; ARTICLE; CONTROLLED STUDY; HEALTH CARE COST; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; MEDICAL PROFESSION; PRIORITY JOURNAL; TUBERCULOSIS; UNITED STATES;

ADULT; AGED; AGED, 80 AND OVER; ANTITUBERCULAR AGENTS; FEMALE; HUMANS; ISONIAZID; LIVER; MALE; MASSACHUSETTS; MIDDLE AGED; PATIENT COMPLIANCE; RIFAMPIN; TREATMENT OUTCOME; TUBERCULOSIS; YOUNG ADULT;

EID: 67651111660     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/600394     Document Type: Article

References (17)

1. Centers for Disease Control and Prevention. Trends in tuberculosis, 2006-United States. MMWR Morb Mortal Wkly Rep 2007; 56:245-50.
2. Centers for Disease Control and Prevention, Division of Tuberculosis Elimination. The difference between latent TB infection and active TB disease. 2005. Available at: http://www.cdc.gov/nchstp/tb/pubs/tbfact- sheets/250101.pdf. Accessed 1 January 2007.
3. Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society. MMWR Recomm Rep 2000; 49(RR-6):1-51.
4. International Union Against Tuberculosis, Committee on Prophylaxis. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. Bull World Health Organ 1982; 60:555-64.
5. Isoniazid prevention of tuberculosis. Lancet 1983; 1:395-6.
6. Menzies D, Dion M-J, Rabinovitch B, Mannix S, Brassard P, Schwartzman K. Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months. Am J Respir Crit Care Med 2004; 170:445-9.
7. Lardizabal A, Passannante M, Kojakali F, Hayden C, Reichman LB. Enhancement oftreatment completion for latent tuberculosis infection with 4 months of rifampin. Chest 2006; 130:1712-7.
8. Page KR, Sifakis F, Montes de Oca R, et al. Improved adherence and less toxicity with rifampin vs isoniazid for treatment of latent tuberculosis. Arch Intern Med 2006; 166:1863-70.
9. Cook PP, Maldonado RA, Yarnell CT, Holbert D. Safety and completion rate of short-course therapy for treatment of latent tuberculosis infection. Clin Infect Dis 2006; 43:271-5.
10. Spyridis NP, Spyridis PG, Gelesme A, et al. The effectiveness of a 9- month regimen of isoniazid alone versus 3- and 4-month regimens of isoniazid plus rifampin for treatment of latent tuberculosis infection in children: results of an 11-year randomized study. Clin Infect Dis 2007; 45:715-22.
11. Jasmer RM, Nahid P, Hopewell PC. Clinical practice: latent tuberculosis infection. N Engl J Med 2002; 347:1860-6.
12. Menzies D, Long R, Trajman A, et al. Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection. Ann Intern Med 2008; 149:689-97.
13. American Thoracic Society; Centers for Disease Control and Prevention; Infectious Diseases Society of America. Treatment of tuberculosis.
14. MMWR Recomm Rep 2003; 52(RR-11):1-77 (erratum: MMWR Recomm Rep 2005; 53[51]:1203).
15. Saukkonen JJ, Cohn DL, Jasmer RM, et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 2006; 174:935-52.
16. Hong Kong Chest Service, Tuberculosis Research Centre, Madras/British Medical Research Council. A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Am Rev Respir Dis 1992; 145:36-41.
17. Polesky A, Farber HW, Goddlieb DJ, et al. Rifampin preventive therapy for tuberculosis in Boston's homeless. Am J Respir Crit Care Med 1996; 154:1473-7.